Xenograft are the cells of one species transplanted to another species.
Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.
Pancreatic cancer is lethal in about 95% of cases mostly due to failure of first-line therapy gemcitabine. AntiCancer Inc.'s oral methioninase (AC 00619), which is in late pre-clinical development as an anti-cancer as well as an anti-aging drug, has now been shown to overcome gemcitabine resistance in mouse models of human pancreatic cancer, including AntiCancer's patient-derived orthotopic xenograft mouse models.
A surprising form of cell-to-cell communication in glioblastoma promotes global changes in recipient cells, including aggressiveness, motility, and resistance to radiation or chemotherapy.
Researchers at Columbia University Irving Medical Center have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.
Glioblastoma multiforme (GBM) is an incredibly deadly brain cancer and presents a serious black box challenge. It's virtually impossible to observe how these tumors operate in their natural environment and animal models don't always provide good answers.
Glioblastoma is the most common and aggressive form of brain cancer. Response to standard-of-care treatment is poor, with a two-year survival rate of only 15 percent.
Existing microscopy-based methods of detecting apoptosis, such as TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling), have limited quantitative capabilities due to insufficient signal-to-noise ratios.
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer.
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of patients, suggesting that as-yet unidentified variations among tumors result in distinct paths of disease progression and response to therapy.
A group of researchers at the Spanish National Cancer Research Centre have identified a protein called RanBP6 as a new regulator of EGFR. In a paper published in Nature Communications they show how silencing of RanBP6 promoted glioma growth, by upregulating EGFR expression.
A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation therapy.
Multiple myeloma is the second most common blood cancer in the United States. Thirty to 50 percent of multiple myeloma patients have extra copies of the gene that encodes the enzyme ADAR1.
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs.
The first Global PDX Directory for proprietary and open source PDX models is being introduced by Cambridge (UK) based benefit corporation, Repositive, at the American Association for Cancer Research’sInternational Conference, on Molecular Targets and Cancer Therapeutics, hosted in conjunction with the European Organisation for Research and Treatment of Cancer and the National Cancer Institute, in Philadelphia, USA, 26-30 October 2017.
New research from The University of Texas Health Science Center at San Antonio and U.S. Department of Veterans Affairs has identified the molecular mechanism that causes kidney cancer to resist drug treatment.
Howard Hughes Medical Institute (HHMI) scientists have created an extensive resource for studying pediatric cancers, which they are sharing widely to help accelerate research.
Seventh Wave Laboratories, a consulting-based contract research organization that assesses the safety and efficacy of pharmaceutical products and medical devices, has announced an exclusive collaboration with Yecuris Corporation, a global leader in the development and use of humanized models in drug development research.
The goal of cancer therapy is to destroy the tumor or stop it from growing and spreading to other parts of the body.
Failure of hormone deprivation therapy, which is used to slow prostate cancer in patients, leads to castration-resistant prostate cancer, a lethal form of advanced disease with limited treatment options.